OxyContin Abuse-Deterrent Postmarketing Data Are In. Now What?
Executive Summary
Purdue’s postmarketing studies leave many unanswered questions about reformulated OxyContin, including the ‘million-dollar’ question of its impact on addiction. Advisory committee members ask for clarity on what constitutes ‘meaningful reduction’ in abuse and advise FDA on what to tell the public about the data.
You may also be interested in...
Did OxyContin Labeling Change Help Fuel Opioid Epidemic? Republicans Want More Data From FDA
Members of House Energy & Commerce Committee reiterate concerns that 2001 label revision may have been used to help promote higher dosage and longer-term prescriptions of OxyContin. J&J boosts opioid litigation settlement offer to $5bn.
OxyContin Abuse Deterrent Formulation Voted Beneficial By FDA Panel, But Questions Remain
Label change is one option after US advisory committee review of Purdue’s postmarketing studies concludes reformulated OxyContin ‘meaningfully reduced abuse’ by non-oral routes, but finds there is not evidence to show such reduction via all routes or that ADF reduced risk of opioid overdose.
Abuse-Deterrent Opioids Could Gain Significant First-Mover Advantage Under FDA Guidance
FDA recommends head-to-head studies against already marketed products – an unusual development policy for the agency.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: